Navigation Links
China Shenghuo Reports Unaudited Financial Results for the Second Quarter of 2009
Date:8/14/2009

ion compared with operating loss of $1.22 million for the same period of 2008.

Net loss for the second quarter of 2009 was $3.78 million, or $ (0.19) per basic and diluted share. This compares to a net loss of $1.54 million, or $(0.08) per basic and diluted share for the same period of 2008.

Balance Sheet

As of June 30, 2009, the Company's total cash and cash equivalents amounted to $0.7 million as compared with $1.6 million as of December 31, 2008. Total shareholders' equity amounted to $0.7 million as of June 30, 2009.

Drugs Pipeline

China Shenghuo has a number of drugs currently in phase II clinical trials with the State Food and Drug Administration (SFDA) for prescription use. The Company's drug portfolio development strategy mainly focuses on three major markets -- cardio- and cerebro-vascular diseases, peptic ulcer diseases and general health products. Below is the list of drugs and their anticipated SFDA approval timetable:


    Drugs Name                   Intended Use                  Anticipated
                                                              Approval Year
    Levofloxacin Hydrochloride
     Soft Capsule                Antibiotic applications           2009
    Brufen Soft Capsule          Fever and headache                2009
                                  caused by influenza, colds
                                  and acute pharyngitis
    Dencichine Hemostat          Anti-hemorrhagic applications     2011
    Wei Dingkang Soft Capsule    Peptic ulcer                      2011

Business Update

Mr. Lan concluded, "Strong product-development capabilities, existing product pipelines and those products entering into clinical-research stages are helping to generate meaningful year-over-year top-line growth as we continue our efforts on expanding market share in the vast cardio- and cerebro-vascular
'/>"/>

SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where ... DNA signatures within the same cancer. Such differences ... treatment strategies. , Firstly they confirmed the mutual ... KRAS or BRAF mutation. Secondly, they found that ... have that specific mutation present uniformly throughout the ...
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... that can provide primary care for low-income patients ... and insurance companies while improving patient health, researchers ... suggests that health clinics that avoid costs associated ... by lowering hospital admission rates and emergency room ... Penn State Altoona. , The researchers estimated ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2
... recommended treatments, study found , FRIDAY, May 28 (HealthDay ... designed to review current research and guidelines, doctors made ... patients with high blood pressure, a new study reports. ... reflected in the practices of community physicians remains a ...
... Chase Cancer Center investigators find that pancreatic cancer patients who ... patients without circulating tumor cells. Additionally, the team has uncovered ... and some may predict worse outcomes than others. Benjamin ... will present the study at the 46th Annual Meeting of ...
... the final details on how two stroke-prevention procedures are safe ... stroke, though their effectiveness does vary by age, say researchers ... Public Health in collaboration with other North American stroke investigators. ... Journal of Medicine (NEJM) May 26, the researchers say ...
... ... range of crystalens to benfit the patients. , ... (Vocus) -- Dr. Khanna and crystal lens have had a symbiotic relationship ... has especially been helpful in people who have undergone radial RK or macular degeneration. ...
... to be self-centered, competitive, U.S. research shows , FRIDAY, May ... reveals that American college students are not quite as empathetic ... drop in empathy after the year 2000," co-author Sara Konrath, ... Research, said in a news release. "College kids today are ...
... brain, still befuddles patients and researchers, , FRIDAY, May 28 ... be a lifeline to the future. And more aggressive, high-dose ... there,s a downside, too: Chemotherapy is linked to a mental ... dismissed as "all in your head," but that,s no longer ...
Cached Medicine News:Health News:Putting New Medical Guidelines Into Practice Often Difficult 2Health News:Circulating tumor cells correlate with poorer survival in pancreatic cancer patients 2Health News:Age is a factor in choosing between two comparable stroke-prevention procedures 2Health News:Khannna Institute to offer Crystalens in Quarter Diopter Steps 2Health News:Today's College Students More Likely to Lack Empathy 2Health News:Making Your Way Through the Fog of Chemotherapy 2Health News:Making Your Way Through the Fog of Chemotherapy 3
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Pneumatic oscillating saw, 35k cpm, available with various hose connector styles....
... Motor Module, with hand throttle. Accepts all ... , 10ft. air hose 9000-000, or existing ... air hose 9013-000, or existing hose with ... 9014-000, or existing hose with 3M connector ...
Pneumatic extended oscillating saw, 35k cpm, available with various hose connector styles....
Pneumatic pencil-grip wire driver, 3000 rpm, available with various hose connector styles....
Medicine Products: